2000
Prognostic significance of cyclin D1 protein levels in early‐stage larynx cancer treated with primary radiation
Yoo S, Carter D, Turner B, Sasaki C, Son Y, Wilson L, Glazer P, Haffty B. Prognostic significance of cyclin D1 protein levels in early‐stage larynx cancer treated with primary radiation. International Journal Of Cancer 2000, 90: 22-28. PMID: 10725854, DOI: 10.1002/(sici)1097-0215(20000220)90:1<22::aid-ijc3>3.0.co;2-t.Peer-Reviewed Original ResearchConceptsEarly-stage larynx cancerLocal relapsePrognostic significanceLarynx cancerTotal median dosePrimary radiation therapySquamous cell carcinomaCell nuclear antigen levelsParaffin-embedded specimensSignificant clinical implicationsCase-control designPercent distributionLarynx cancer patientsCyclin D1 protein levelsCyclin D1 levelsMedian doseControl patientsLocal recurrenceAntigen levelsCancer patientsCell carcinomaDaily fractionsRadiation therapyIndex caseClinical information
1998
Intraoperative brachytherapy, laryngopharyngoesophagectomy, and gastric transposition for patients with recurrent hypopharyngeal and cervical esophageal carcinoma
Wilson L, Chung J, Haffty B, Cahow E, Sasaki C, Son Y. Intraoperative brachytherapy, laryngopharyngoesophagectomy, and gastric transposition for patients with recurrent hypopharyngeal and cervical esophageal carcinoma. The Laryngoscope 1998, 108: 1504-1508. PMID: 9778290, DOI: 10.1097/00005537-199810000-00014.Peer-Reviewed Original ResearchConceptsExternal beam radiationGastric transpositionCervical esophagusLocal controlMedian doseRecurrent carcinomaActuarial local controlCervical esophageal carcinomaLymphvascular space invasionTotal median doseLymph node dissectionGood local controlAcceptable risk profileActuarial survivalNode dissectionFacial painNodal involvementOverall survivalRecurrent diseaseCervical abscessIntraoperative brachytherapyMale patientsMedian ageMucosal hemorrhageFacial edema
1997
Total skin electron beam therapy followed by adjuvant psoralen/ultraviolet-A light in the management of patients with T1 and T2 cutaneous T-cell lymphoma (mycosis fungoides)
Quirós P, Jones G, Kacinski B, Braverman I, Heald P, Edelson R, Wilson L. Total skin electron beam therapy followed by adjuvant psoralen/ultraviolet-A light in the management of patients with T1 and T2 cutaneous T-cell lymphoma (mycosis fungoides). International Journal Of Radiation Oncology • Biology • Physics 1997, 38: 1027-1035. PMID: 9276369, DOI: 10.1016/s0360-3016(97)00127-2.Peer-Reviewed Original ResearchConceptsTotal skin electron beam therapyDisease-free survivalT2 patientsCrude relapse rateAdjuvant therapyOverall survivalElectron beam therapyRelapse rateEntire cohortMedian disease-free survivalCutaneous T-cell lymphomaBeam therapySalvage of recurrencesAdjuvant systemic therapyEarly-stage patientsManagement of patientsT-cell lymphomaTopical nitrogen mustardDays/weekCombination of therapiesGy/dayTreatments/weekPUVA patientsMedian followSalvage therapyBioreductive alkylating agent porfiromycin in combination with radiation therapy for the management of squamous cell carcinoma of the head and neck
Haffty B, Son Y, Wilson L, Papac R, Fischer D, Rockwell S, Sartorelli A, Ross D, Sasaki C, Fischer J. Bioreductive alkylating agent porfiromycin in combination with radiation therapy for the management of squamous cell carcinoma of the head and neck. International Journal Of Cancer 1997, 5: 235-245. PMID: 9372546, DOI: 10.1002/(sici)1520-6823(1997)5:5<235::aid-roi4>3.0.co;2-z.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaWhite blood cell countPhase I trialCell carcinomaRadiation therapyMitomycin CNonhematological toxicitiesI trialStage III/IV squamous cell carcinomaCourse of RTTotal median doseAcceptable toxicity profilePhase III trialsCurrent ongoing trialsDisease survival ratesDaily radiation therapyBlood cell countHypoxic cell cytotoxinActuarial survivalHemoglobin nadirsAdvanced diseaseMedian doseIII trialsOngoing trialsMultiinstitutional trial